


**GENNEX LABORATORIES LIMITED**

 REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325  
 Statement of Audited Results for the Quarter and Year Ended 31st March, 2017

PART I		(Rs. in lakhs)				
Sl. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>Income from Operations</b>					
	Sales/Income from Operations	1138.57	1125.05	1049.86	4330.64	4031.24
	Less: Excise Duty	30.68	66.91	54.96	157.89	178.03
a	Net Sales/Income from Operations	1107.89	1058.14	994.90	4172.75	3853.21
b	(b) Other operating Income	0.40	0.26	0.39	17.97	2.39
	<b>Total Income from operations (net)</b>	<b>1108.29</b>	<b>1058.40</b>	<b>995.29</b>	<b>4190.72</b>	<b>3855.60</b>
2	<b>Expenses</b>					
	(a) Cost of material consumed	661.75	619.39	630.66	2356.98	2358.37
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	65.78
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-45.60	-3.72	-96.82	35.71	-161.06
	(d) Employee benefit expense	157.24	118.25	118.75	495.88	411.56
	(e) Finance Costs	29.14	7.72	13.85	70.54	50.38
	(f) Depreciation and amortisation expense	22.76	20.60	19.64	83.94	83.60
	(g) Other expenses	269.09	204.54	218.29	849.48	761.28
	<b>Total expenses</b>	<b>1094.38</b>	<b>966.78</b>	<b>904.37</b>	<b>3892.53</b>	<b>3569.91</b>
3	Profit(+)/Loss(-) from operations before other income and exceptional items (1-2)	13.91	91.62	90.92	298.19	285.69
4	Other income	-0.13	6.22	5.09	11.89	21.43
5	Profit(+)/Loss(-) from ordinary activities before exceptional items (3+4)	13.78	97.84	96.01	310.08	307.12
6	Exceptional items	0.00	0	1.15	0	-3.78
7	Profit(+)/Loss(-) from ordinary activities before tax (5+6)	13.78	97.84	97.16	310.08	303.34
8	Tax expense	36.58	-0.85	69.24	39.65	69.65
9	Profit(+)/Loss(-) from ordinary activities after tax (7-8)	-22.80	98.69	27.92	270.43	233.69
10	Extraordinary items (net of tax expense Rs. Lakhs)	0	0	0	0	0
11	Net Profit(+)/Loss(-) for the period (9+10)	-22.80	98.69	27.92	270.43	233.69
12	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03
13	Reserve excluding Revaluation Reserves				1829.09	1558.66
14. i	Earning Per Share (before extraordinary items) ( of Rs. 1 each ) (not annualised) :					
	(a) Basic	-0.018	0.078	0.022	0.214	0.185
	(b) Diluted	-0.018	0.078	0.022	0.214	0.185
14. ii	Earning Per Share (after extraordinary items) ( of Rs. 1 each ) (not annualised) :					
	(a) Basic	-0.018	0.078	0.022	0.214	0.185
	(b) Diluted	-0.018	0.078	0.022	0.214	0.185

## Standalone Statement of assets and liabilities.

( Rs. In Lakhs )

Particulars	31-03-2017		31-03-2016
<b>A) EQUITY AND LIABILITIES</b>	<b>Audited</b>		<b>Audited</b>
<b>1 Shareholders' Funds:</b>			
a) Share Capital	1265.03		1265.03
b) Reserves and Surplus	1829.09		1558.65
	<b>3094.12</b>		<b>2823.68</b>
<b>2 Non - Current Liabilities</b>			
a) Long-term borrowings			
- Secured	8.55		3.05
- Unsecured	10.01		11.72
b) Deferred Tax Adjustment	94.89		98.31
c) Long-term provisions	0		0
	<b>113.45</b>		<b>113.08</b>
<b>3 Current Liabilities</b>			
a) Short-term borrowings			
- Secured	375.16		223.79
- Unsecured	5.96		4.25
b) Trade payables	967.25		704.65
c) Others current liabilities	315.91		233.88
d) short-term provisions	50.06		75.78
	<b>1714.34</b>		<b>1242.35</b>
<b>TOTAL</b>	<b>1714.34</b>		<b>1242.35</b>
<b>GRAND TOTAL (1+2+3)</b>	<b>4921.91</b>		<b>4179.11</b>
<b>B) ASSETS</b>			
<b>1 Non-Current Assets</b>			
a) Fixed Assets			
i) Tangible Assets	1574.11		1557.92
ii) Intangible Assets	0.00		0.00
b) Non-Current Investments	701.00		701.00
c) Other non-current assets	22.14		23.97
	<b>2297.25</b>		<b>2282.89</b>
<b>2 Current Assets</b>			
a) Inventories	289.04		294.20
b) trade receivable	1029.56		695.93
c) Cash and Cash equivalents	62.95		84.78
d) Short-term loans and Advances	1242.03		817.38
e) Other current assets	1.08		3.93
	<b>2624.66</b>		<b>1896.22</b>
<b>TOTAL</b>	<b>2624.66</b>		<b>1896.22</b>
<b>GRAND TOTAL (1+2)</b>	<b>4921.91</b>		<b>4179.11</b>

## NOTES:

- 1) The above audited results for the quarter and year ended March 31,2017 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 30, 2017.
- 2) Tax Expenses include Current Tax and Deferred tax.
- 3) The major operations of the company relate to only one segment viz., Bulk Drugs, Biotech Products & Intermediates. As such there is no separate reportable segment under Accounting Standard 17 of Segment Reporting.
- 4) The figures of the current quarter ending on 31st March,2017 are the balancing figures between the Audited figures of the full Financial year ended 31st March,2017 & the published year to date figures upto 3rd Quarter ended December 31st,2016.
- 5) Previous period's figures have been regrouped / rearranged wherever considered necessary.

Place: Hyderabad  
Date: 30.05.2017

For and on behalf of the Board  
For Gennex Laboratories Limited

sd/-  
Arihant Baid  
( Managing Director )